Related Research Articles
The nomenclature of monoclonal antibodies is a naming scheme for assigning generic, or nonproprietary, names to monoclonal antibodies. An antibody is a protein that is produced in B cells and used by the immune system of humans and other vertebrate animals to identify a specific foreign object like a bacterium or a virus. Monoclonal antibodies are those that were produced in identical cells, often artificially, and so share the same target object. They have a wide range of applications including medical uses.
Drug nomenclature is the systematic naming of drugs, especially pharmaceutical drugs. In the majority of circumstances, drugs have 3 types of names: chemical names, the most important of which is the IUPAC name; generic or nonproprietary names, the most important of which are international nonproprietary names (INNs); and trade names, which are brand names. Under the INN system, generic names for drugs are constructed out of affixes and stems that classify the drugs into useful categories while keeping related names distinguishable. A marketed drug might also have a company code or compound code.
Imgatuzumab (INN) is a humanized monoclonal antibody designed for the treatment of cancer. It is an anti-EGFR antibody that acts as an immunomodulator.
Parsatuzumab (INN) is a humanized monoclonal antibody designed for the treatment of cancer. It acts as an immunomodulator and binds to EGFL7.
Perakizumab (INN) is a humanized monoclonal antibody designed for the treatment of arthritis. It binds to IL17A and acts as an immunomodulator.
Lifastuzumab vedotin is an experimental monoclonal antibody-drug conjugate designed for the treatment of cancer.
Sofituzumab vedotin is a monoclonal antibody designed for the treatment of ovarian cancer.
Ulocuplumab is a monoclonal antibody designed for the treatment of hematologic malignancies.
Pinatuzumab vedotin is a monoclonal antibody designed for the treatment of B-cell malignancies.
Seribantumab is a monoclonal antibody designed for the treatment of cancer.
Brontictuzumab is a humanized monoclonal antibody designed for the treatment of cancer.
Vanucizumab is an experimental humanized monoclonal antibody designed for the treatment of cancer.
Vandortuzumab vedotin is a humanized monoclonal antibody designed for the treatment of cancer.
Plozalizumab is a humanized monoclonal antibody designed for the treatment of diabetic nephropathy and arteriovenous graft patency.
Domagrozumab (PF-06252616) (INN) is a humanized monoclonal antibody designed for the treatment of Duchenne muscular dystrophy.
Brazikumab is a human monoclonal antibody designed for the treatment of Crohn's disease. that targets IL-23.
Letolizumab is a humanized monoclonal antibody designed for the treatment of inflammatory diseases.
Oleclumab is a human monoclonal antibody targeting the ectonucleotidase CD73 that was designed for the treatment of pancreatic and colorectal and other cancers.
Carotuximab (INN) (TRC-105) is a chimeric monoclonal antibody designed for the treatment of cancer.
References
- ↑ Statement On A Nonproprietary Name Adopted By The USAN Council - Crotedumab, American Medical Association .
- ↑ World Health Organization (2015). "International Nonproprietary Names for Pharmaceutical Substances (INN). Proposed INN: List 114" (PDF). WHO Drug Information. 29 (4).
- ↑ Peterson SM, Hutchings CJ, Hu CF, Mathur M, Salameh JW, Axelrod F, Sato AK (April 2023). "Discovery and design of G protein-coupled receptor targeting antibodies". Expert Opinion on Drug Discovery. 18 (4): 417–428. doi: 10.1080/17460441.2023.2193389 . PMID 36992620.
 | This monoclonal antibody–related article is a stub. You can help Wikipedia by expanding it. |